Safety profile of baricitinib for the treatment of rheumatoid arthritis up to 9.3 years: an updated integrated safety analysis

Sonraí bibleagrafaíochta
Príomhchruthaitheoirí:	Taylor, P, Takeuchi, T, Burmester, G, Durez, P, Smolen, J, Deberdt, W, Zhong, J, Teres, JR, Bello, N, Winthrop, K, Pope, J
Formáid:	Conference item
Teanga:	English
Foilsithe / Cruthaithe:	Journal of Rheumatology 2022

Míreanna comhchosúla

Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database
de réir: Taylor, P, et al.
Foilsithe / Cruthaithe: (2021)

Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis
de réir: Weinblatt, M, et al.
Foilsithe / Cruthaithe: (2017)

Cardiovascular safety - Update from up to 6 years of treatment with baricitinib in rheumatoid arthritis clinical trials
de réir: Weinblatt, M, et al.
Foilsithe / Cruthaithe: (2018)

Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis
de réir: Taylor, P, et al.
Foilsithe / Cruthaithe: (2019)

Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis
de réir: Gerd Burmester, et al.
Foilsithe / Cruthaithe: (2020-02-01)

Efficacy and safety of switching from adalimumab to baricitinib: Phase 3 data in patients with rheumatoid arthritis
de réir: Taylor, P, et al.
Foilsithe / Cruthaithe: (2016)

Efficacy and safety of switching from adalimumab to baricitinib: phase 3 data in patients with rheumatoid arthritis
de réir: Taylor, P, et al.
Foilsithe / Cruthaithe: (2017)

Real-world comparative effectiveness and safety of tofacitinib and baricitinib in patients with rheumatoid arthritis
de réir: Naoki Iwamoto, et al.
Foilsithe / Cruthaithe: (2021-07-01)

Baricitinib for the treatment of rheumatoid arthritis
de réir: Ivan Urits, et al.
Foilsithe / Cruthaithe: (2020-12-01)

Assessment of pain improvement in rheumatoid arthritis patients treated with baricitinib, who were inadequate responders to methotrexate and tumor necrosis factor inhibitors
de réir: Taylor, P, et al.
Foilsithe / Cruthaithe: (2019)

Baricitinib versus placebo or adalimumab in rheumatoid arthritis
de réir: Taylor, P, et al.
Foilsithe / Cruthaithe: (2017)

Baricitinib: Early vs. delayed start in patients with rheumatoid arthritis
de réir: Taylor, P, et al.
Foilsithe / Cruthaithe: (2018)

Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate.
de réir: Keystone, E, et al.
Foilsithe / Cruthaithe: (2015)

Baricitinib inhibits structural joint damage progression in patients with rheumatoid arthritis—a comprehensive review
de réir: Paul Emery, et al.
Foilsithe / Cruthaithe: (2021-01-01)

Baricitinib exposure during pregnancy in rheumatoid arthritis
de réir: Giulia Costanzo, et al.
Foilsithe / Cruthaithe: (2020-01-01)

Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis with 3 years of treatment: results from a long-term study
de réir: Smolen, JS, et al.
Foilsithe / Cruthaithe: (2020)

Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis with 3 years of treatment: Results from a long-term study
de réir: Smolen, JS, et al.
Foilsithe / Cruthaithe: (2020)

Safety and efficacy of baricitinib through 128 weeks in an open-label, longterm extension study in patients with rheumatoid arthritis
de réir: Keystone, EC, et al.
Foilsithe / Cruthaithe: (2017)

Summary of indirect comparison to evaluate efficacy of baricitinib with targeted synthetic and biologic disease anti-rheumatic drugs in patients with rheumatoid arthritis
de réir: Emery, P, et al.
Foilsithe / Cruthaithe: (2019)

Rapid and sustained pain improvement in rheumatoid arthritis patients treated with baricitinib compared to adalimumab or placebo
de réir: Taylor, P, et al.
Foilsithe / Cruthaithe: (2017)

A JAK inhibitor for treatment of rheumatoid arthritis: the baricitinib experience
de réir: Taylor, PC, et al.
Foilsithe / Cruthaithe: (2023)

Association between baseline haemoglobin levels and radiographic joint damage progression in patients with rheumatoid arthritis treated with baricitinib or standard of care
de réir: Moeller, B, et al.
Foilsithe / Cruthaithe: (2019)

A review of safety outcomes from clinical trials of baricitinib in rheumatology, dermatology and COVID-19
de réir: Bieber, T, et al.
Foilsithe / Cruthaithe: (2022)

Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis
de réir: Paul Emery, et al.
Foilsithe / Cruthaithe: (2020-05-01)

Efficacy and safety of switching from adalimumab to baricitinib: long-term data from phase 3 extension study in patients with rheumatoid arthritis
de réir: Weinblatt, M, et al.
Foilsithe / Cruthaithe: (2018)

Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy
de réir: Taylor, P, et al.
Foilsithe / Cruthaithe: (2022)

New alternative in the treatment of rheumatoid arthritis: clinical utility of baricitinib
de réir: Kawalec P, et al.
Foilsithe / Cruthaithe: (2019-02-01)

Efficacy and Safety of Baricitinib in Chinese Rheumatoid Arthritis Patients and the Subgroup Analyses: Results from Study RA-BALANCE
de réir: Yue Yang, et al.
Foilsithe / Cruthaithe: (2020-09-01)

Cutaneous eruption after commencing baricitinib for rheumatoid arthritis
de réir: Rosemary Akinbisehin, et al.
Foilsithe / Cruthaithe: (2024-06-01)

Correction to: Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis
de réir: Paul Emery, et al.
Foilsithe / Cruthaithe: (2020-07-01)

Effect of baricitinib and adalimumab in reducing pain and improving function in patients with rheumatoid arthritis in low disease activity: exploratory analyses from RA-BEAM
de réir: Fautrel, B, et al.
Foilsithe / Cruthaithe: (2019)

Safety and Effectiveness of Baricitinib in Chinese Patients with Moderate-to-Severe Rheumatoid Arthritis: 24-Week Results from a Post-Marketing Safety Study
de réir: Chan-yuan Wu, et al.
Foilsithe / Cruthaithe: (2023-09-01)

Efficacy and safety of baricitinib in rheumatoid arthritis patients with moderate renal impairment: a multicenter propensity score matching study
de réir: Akira Maeyama, et al.
Foilsithe / Cruthaithe: (2024-12-01)

Rapid and concurrent improvements in patient-reported outcomes of rheumatoid arthritis with baricitinib in RA-BEAM
de réir: Strand, V, et al.
Foilsithe / Cruthaithe: (2021)

Problems of pain and quality of life in rheumatoid arthritis: focus on baricitinib
de réir: A. E. Karateev
Foilsithe / Cruthaithe: (2020-09-01)

Baricitinib: key results of long-term use in rheumatoid arthritis
de réir: N. V. Chichasova, et al.
Foilsithe / Cruthaithe: (2024-08-01)

Efficacy of baricitinib combined with iguratimod in the treatment of refractory rheumatoid arthritis
de réir: CHEN Jianming, LEI Meihong, ZHANG Lanxia
Foilsithe / Cruthaithe: (2023-11-01)

Tofacitinib and Baricitinib in Type 2 Diabetic Patients with Rheumatoid Arthritis
de réir: Cristina Martinez-Molina, et al.
Foilsithe / Cruthaithe: (2024-02-01)

Patient disease trajectories in baricitinib-treated patients with rheumatoid arthritis and inadequate response to methotrexate
de réir: Taylor, P, et al.
Foilsithe / Cruthaithe: (2019)

Characterization and changes of lymphocyte subsets in baricitinib-treated patients with rheumatoid arthritis: an integrated analysis
de réir: Tanaka, Y, et al.
Foilsithe / Cruthaithe: (2018)